文献速递精神分裂症与精神病性障碍

沉浸式虚拟现实辅助疗法治疗精神分裂症谱系障碍患者持续性言语幻听:丹麦Challenge评估者盲法随机临床试验

Immersive virtual reality-assisted therapy targeting persistent auditory verbal hallucinations in patients diagnosed with schizophrenia spectrum disorders in Denmark: the Challenge assessor-masked, randomised clinical trial.
PubMed 文献 · Lancet Psychiatry · 2025-07-03

这项在丹麦三地区门诊开展的评估者盲法随机优效试验,将271例对足量抗精神病药反应不足的成人精神分裂症患者按1:1分配至Challenge-VRT组(7次每周沉浸式VR会话+2次强化会话)或强化照常治疗组。

要点

  • 幻听频率在12周和24周均显著下降,其他次要结局未见显著差异。
  • 6例严重不良事件可能与干预相关,包括5例幻听加重入院和1例自伤,无死亡。

核心结论

  • Challenge-VRT对精神分裂症患者言语幻听的严重程度具有短期疗效,支持进一步开发与评估沉浸式VR疗法。

研究设计与样本

  • 随机、评估者盲法、平行组优效性临床试验,在丹麦三个地区门诊精神科招募成人精神分裂症患者。
  • 纳入标准为年龄≥18岁、言语幻听持续至少3个月且对抗精神病药反应不足;排除无法识别主导声音、当前物质依赖及器质性脑病者。
  • 271例参与者按1:1随机分配至Challenge-VRT组(n=140)或强化照常治疗组(n=131),采用置换区组(区组大小12)按中心和抗精神病药治疗分层,分配隐藏。
  • Challenge-VRT为每周1次共7次沉浸式VR会话加2次强化会话,对照组为频率和时长匹配的强化照常治疗。
  • 主要结局为基线后12周临床医生评定的PSYRATS-AH总分,分析遵循意向性治疗原则并使用线性混合模型。

主要发现

  • 其他次要结局(PSYRATS-AH distress、声音权力差异量表、声音接纳与行动量表、APPROVE-Voices自信回应子量表、个人与社会表现量表)在12周均无显著差异。
  • 干预总体耐受良好;6例严重不良事件可能与Challenge-VRT相关(5例幻听加重入院、1例自伤),试验期间无死亡。

关键数值与推荐

  • 纳入标准包括年龄≥18岁、言语幻听持续至少3个月、对抗精神病药反应不足。
  • 干预为7次每周沉浸式VR会话加2次强化会话,对照为频率和时长匹配的强化照常治疗。

临床怎么用

  • 对于对抗精神病药反应不足的言语幻听患者,可考虑在强化照常治疗基础上联合Challenge-VRT以短期减轻幻听严重程度和频率。
  • 实施中需监测幻听加重和自伤风险,试验中6例严重不良事件可能与干预相关。
  • 其他结局如痛苦、声音权力、接纳与行动、自信回应及社会功能在12周未见显著改善,不应据此宣称全面获益。

局限性

  • 原文未报告盲法对参与者和治疗实施者的实施细节。
  • 未收集族裔数据。
  • 其他次要结局均无显著差异,短期疗效的临床意义需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Auditory verbal hallucinations are among the most frequent and debilitating symptoms of schizophrenia spectrum disorders (henceforth termed schizophrenia), particularly in patients with treatment-resistant symptoms. Current treatment options have suboptimal response rates and innovative interventions are needed. This study aimed to evaluate the efficacy and safety of a novel immersive virtual reality-assisted therapy (Challenge-VRT) for auditory verbal hallucinations. METHODS: In this randomised, assessor-masked, parallel-group superiority clinical trial, patients with schizophrenia were recruited from outpatient psychiatric services across three Danish regions. Key inclusion criteria were age 18 years or older, auditory verbal hallucinations for at least 3 months, and insufficient symptom response to antipsychotic medication. Exclusion criteria included being unable to identify a dominant voice, current substance dependence, and organic brain disorder. Participants were randomly assigned (1:1) via a secure web-based system using permuted blocks (block size 12), stratified by site and antipsychotic treatment. Allocation was concealed from outcome assessors. Participants were assigned to either Challenge-VRT (seven weekly immersive virtual reality sessions plus two booster sessions) or a control intervention of enhanced treatment-as-usual, matched in frequency and duration. Challenge-VRT was co-developed with individuals with lived experience of auditory verbal hallucinations. The primary outcome was clinician-rated auditory verbal hallucination severity measured by the Psychotic Symptoms Rating Scales-Auditory Hallucinations total score (PSYRATS-AH) at 12 weeks post baseline. Secondary outcomes were PSYRATS-AH frequency, PSYRATS-AH-Distress, The Voice Power Differential Scale, the Voices Acceptance and Action Scale, the Assertive Responding to Voices subscale from the Approve-Voices, and the Personal and Social Performance Scale, all at 12 weeks. Analyses followed the intention-to-treat principle and used linear mixed models. This study is registered with ClinicalTrials.gov, number NCT04661163, and is now completed. FINDINGS: Between Nov 16, 2020, and June 14, 2023, 399 patients were referred for potential study inclusion, 62 patients were excluded (declined to participate or unable to be contacted), and 337 were assessed for eligibility. Of these, 66 did not meet the inclusion criteria. 271 participants were randomly assigned to Challenge-VRT (n=140) or enhanced treatment-as-usual (n=131). One participant was excluded post-randomisation, resulting in 270 included in the analysis of all outcomes. Participants had a mean age of 32·83 years (SD 11·9, range 18-72), 105 (39%) were male, and 165 (61%) were female. No data on ethnicity were collected. At 12 weeks, Challenge-VRT significantly reduced auditory verbal hallucination severity compared with enhanced treatment-as-usual on the PSYRATS-AH (adjusted mean difference -2·26 [95% CI -4·26 to -0·25]; p=0·027; Cohen's d, 0·27). Among secondary outcomes, a significant reduction in PSYRATS-AH frequency was observed in the Challenge-VRT group at both 12 weeks (adjusted mean difference -0·84 [95% CI -1·53 to -0·14]; p=0·018) and 24 weeks (adjusted mean difference -0·86 [95% CI -1·65 to -0·07]; p=0·034). No significant differences were found for other secondary outcomes. The intervention was generally well tolerated. Six serious adverse events occurred that might have been related to the Challenge-VRT intervention (five cases of hospital admission due to exacerbation of auditory verbal hallucinations and one episode of self-harm). No deaths occurred during the trial. INTERPRETATION: Challenge-VRT showed short-term efficacy in reducing the severity of auditory verbal hallucinations in patients with schizophrenia, and the findings support further development and evaluation of immersive virtual reality-based therapies in this population. FUNDING: The Innovation Fund Denmark, Independent Research Fund Denmark, Innovation Fund North Denmark Region, Psychiatry Research Fund North Denmark Region, and The M L Jørgensen and Gunnar Hansen Fund. TRANSLATION: For the Danish translation of the abstract see Supplementary Materials section.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Smith LC, Vernal DL, Mariegaard LS, et al. Immersive virtual reality-assisted therapy targeting persistent auditory verbal hallucinations in patients diagnosed with schizophrenia spectrum disorders in Denmark: the Challenge assessor-masked, randomised clinical trial. Lancet Psychiatry. 2025. PMID: 40617245. doi:10.1016/S2215-0366(25)00161-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。